Navigation Links
Orexigen Therapeutics Reports Corporate and Financial Results for the Second Quarter Ended June 30, 2014
Date:8/7/2014

SAN DIEGO, Aug. 7, 2014 /PRNewswire/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity, today announced corporate and financial results for the second quarter ended June 30, 2014.

"We are making progress with the FDA discussing the alternatives for the post-marketing obligation for evaluation of cardiovascular outcomes, and we are confident that we can reach agreement on these final details of the NB32 review," said Michael Narachi, CEO of Orexigen.

 

Financial results for the three months ended June 30, 2014
For the three months ended June 30, 2014, Orexigen reported a net loss of $24.5 million, or $0.21 per share, as compared to a net loss of $18.2 million, or $0.19 per share, for the second quarter of 2013.

Total operating expenses for the second quarter of 2014 were $23.7 million compared to $19.1 million for the second quarter of 2013. This overall increase in operating expenses reflects an increase in raw materials, inventory, and manufacturing-related expenses and in stock based compensation expense. While Orexigen is responsible for manufacturing NB32, Takeda Pharmaceuticals will reimburse Orexigen for manufacturing related costs, including finished goods.

As of June 30, 2014, Orexigen had $31.1 million in cash and cash equivalents and an additional $102.2 million in marketable securities, for a total of $133.3 million. Orexigen is eligible to receive cash milestone payments of $100 million from Takeda Pharmaceuticals, between US approval and first commercial sale of NB32.

NB32 program update:

  • NB32 (32 mg naltrexone sustained-release (SR)/360 mg bupropion SR), an investigational medicine for weight loss and the maintenance of weight loss: In June 2014, the United States Food and Drug Administration (FDA) extended it
    '/>"/>

  • SOURCE Orexigen Therapeutics, Inc.
    Copyright©2014 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11

    Related medicine technology :

    1. Orexigen Therapeutics to Host Second Quarter 2014 Financial Results Conference Call and Webcast
    2. Orexigen Announces June 10, 2014 PDUFA Action Date for Contrave
    3. Orexigen Resubmits Contrave New Drug Application
    4. Orexigen Therapeutics, Inc. Announces the Closing of its Offering of $115 Million of Convertible Senior Notes
    5. Orexigen Therapeutics to Present at the 25th Annual Piper Jaffray Healthcare Conference
    6. Orexigen Announces Successful Interim Analysis of Contrave Light Study
    7. Orexigen Therapeutics to Host Contrave Light Study Interim Analysis Conference Call and Webcast
    8. Orexigen Therapeutics Reports Business and Financial Results for the Third Quarter Ended September 30, 2013
    9. Orexigen and Takeda Announce Multiple Contrave Data Presentations at the ObesityWeek Meeting in Atlanta
    10. Orexigen Therapeutics Enters Into Agreement with Sanofi to Manufacture Contrave for Territories Outside North America
    11. A Balanced Risk-Benefit Profile Will Propel Orexigen/Takedas Contrave to Become the Most Widely Used Emerging Therapy for the Treatment of Obese and Overweight Patients
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:12/15/2014)... , December 15, 2014 ... drugs for aggressive drug resistant cancers, today announces that ... a private placing from new and existing investors. ... to support the development of its pipeline of innovative ... for its lead drug candidate, BGB324, a first-in-class selective ...
    (Date:12/15/2014)... Investor-Edge has initiated coverage on the ... Lilly and Company (NYSE: LLY ), Nektar Therapeutics ... ), and Novartis AG (NYSE: NVS ). Free ... http://investor-edge.com/register . On Friday, December 12, 2014, the ... Industrial Average lost 1.79%, to finish the day at 17,280.83, ...
    (Date:12/15/2014)... and BOSTON , December 15, 2014 ... structure-guided drug discovery and development company, is pleased to ... the United States relating to its ... in the US significantly strengthens the global patent estate ... markets. The suite of patents recently granted ...
    Breaking Medicine Technology:BerGenBio Completes NOK90 Million Fundraising 2Analysts View on Pharma Equities - Zogenix, Eli Lilly, Nektar Therapeutics, Sanofi, and Novartis 2Analysts View on Pharma Equities - Zogenix, Eli Lilly, Nektar Therapeutics, Sanofi, and Novartis 3Analysts View on Pharma Equities - Zogenix, Eli Lilly, Nektar Therapeutics, Sanofi, and Novartis 4Analysts View on Pharma Equities - Zogenix, Eli Lilly, Nektar Therapeutics, Sanofi, and Novartis 5Heptares Extends Global Patent Protection for GPCR-Focused Drug Discovery Platform With Grant of Core Patents in the United States 2
    ... best policy , , ROCHESTER, ... the use of the drug therapy etanercept ineffective in treating alcoholic ... of alcohol. The results of the study are published in the ... , VIDEO ALERT: Additional audio and ...
    ... 9 at 11:00 am ET to Discuss Phase 2 Study ... SOUTH SAN FRANCISCO, Calif., Dec. 1 ... biopharmaceutical company focused on the development and commercialization of new ... voreloxin in acute myeloid leukemia (AML) will be presented during ...
    Cached Medicine Technology:Mayo Clinic Seeks New Therapies for Alcoholic Hepatitis 2Mayo Clinic Seeks New Therapies for Alcoholic Hepatitis 3Sunesis Announces New Data on Voreloxin for Acute Myeloid Leukemia To Be Presented at ASH 2Sunesis Announces New Data on Voreloxin for Acute Myeloid Leukemia To Be Presented at ASH 3
    (Date:12/17/2014)... 16, 2014 (HealthDay News) -- Greater participation in music ... finds. Researchers followed kids in the nonprofit Harmony ... children in Los Angeles. Over two years, children ... in how the brain processes speech and reading, compared ... the benefits of active participation in music classes occurred ...
    (Date:12/15/2014)... (PRWEB) December 15, 2014 Cancer researchers ... possible underlying genetic causes of deadly malignant pleural mesothelioma. ... research on their website. Click here to read ... University of Hawaii Cancer Center, and New York’s Langone ... malignant pleural mesothelioma patients in an effort to ...
    (Date:12/15/2014)... 2014 OutMarket , a provider ... Social Media Cheat Sheets ,” a guide that exposes ... results on the top ten social media networks. ... drive awareness, engagement, and customer service. It can also ... an impact on new networks and weather constantly changing ...
    (Date:12/15/2014)... SIMSBURY, CT (PRWEB) December 15, 2014 ... in the prestigious Women World Awards in the category ... of a gold award for her weekly career blog ... and practical advice to help professionals elevate their talent ... Her blog, named after her book Networking Ahead ...
    (Date:12/15/2014)... Kenmode Precision Metal Stamping has announced that ... Quality Assurance. He brings more than 15 years ... for manufacturers in the U.S. and abroad. , ... at Sonoco Products Company in the Protective Solutions Division, ... Assurance Manager for Prince Industries, all in the Chicago ...
    Breaking Medicine News(10 mins):Health News:Music Classes Boost Language Skills, Study Says 2Health News:New Study Reveals Genetic Mutations That May Trigger Mesothelioma, According to Surviving Mesothelioma 2Health News:OutMarket Releases Cheat Sheets for Social Media Marketing 2Health News:OutMarket Releases Cheat Sheets for Social Media Marketing 3Health News:Kathy McAfee, America’s Marketing Motivator, Wins Best Blog from Women World Awards 2Health News:Kenmode Precision Metal Stamping Appoints Abid Rashid as Director of Quality Assurance 2
    ... DENVER, Oct. 11 Global Med Technologies(R),Inc. ... medical,information technology company, today reported that its ... exhibitor at the AABB,Annual Meeting and Transfusion ... ) The AABB, founded in 1947, ...
    ... and allows hospital pharmacies to accurately manage costs and ... ... Oct. 11 Omnicell, Inc.,(Nasdaq: OMCL ) a leading provider ... operational efficiency, today,announced the Omnicell WorkflowRx 5.0 central pharmacy automation solution.,With ...
    ... * concentrated Tylenol(R) Infants, Drops Plus Cold ... ... FORT WASHINGTON, Pa., Oct. 11 McNeil Consumer,Healthcare, a division of ... cough and cold products,from the market. When used as directed, these ...
    ... ALOKA Co., Ltd., a pioneer in the,development ... Masanobu Tada as President, and Carlos Faustmann as ... the company,s,wholly-owned European headquarters in Zug, Switzerland, with ... Global Marketing of the company as,general manager since ...
    ... Plan to Give Access to Affordable Health Insurance, ... Cover,All Pennsylvanians, the centerpiece of his "Prescription for Pennsylvania,",was ... held a,town meeting in Erie as part of his ... the need to lower health care costs,and expand coverage. ...
    ... cancer in mice - can replicate and spread in human ... the online open access journal Retrovirology, adds weight to the ... cancer. , The idea that MMTV is involved in human ... the 1990s, researchers detected MMTV in human breast tumors, but ...
    Cached Medicine News:Health News:Global Med Technologies(R), Inc.'s Division, Wyndgate Technologies(R), to Exhibit at 60th Annual AABB Conference 2Health News:Global Med Technologies(R), Inc.'s Division, Wyndgate Technologies(R), to Exhibit at 60th Annual AABB Conference 3Health News:Omnicell Introduces the Next Generation Central Pharmacy Automation Solution 2Health News:Omnicell Introduces the Next Generation Central Pharmacy Automation Solution 3Health News:McNeil Consumer Healthcare is Voluntarily Withdrawing Infants' Cough and Cold Products: 2Health News:McNeil Consumer Healthcare is Voluntarily Withdrawing Infants' Cough and Cold Products: 3Health News:ALOKA Appoints New Management in Europe 2Health News:Governor Rendell Launches 'Tour to Insure' In Erie; 2Health News:Governor Rendell Launches 'Tour to Insure' In Erie; 3Health News:Mouse mammary tumor virus can replicate in human cells 2
    20 GA TITANIUM RETINAL FORCEPS...
    ... Centuries of German Craftsmanship ... surgical instrumentation in the ... them available to you! ... coveted Meisterbrief certificate, which ...
    ... Centuries of German ... finest surgical instrumentation in ... makes them available to ... the coveted Meisterbrief certificate, ...
    ... Centuries of German Craftsmanship ... surgical instrumentation in the ... them available to you! ... coveted Meisterbrief certificate, which ...
    Medicine Products: